title: Diclofenac does not modify morphine bioavailability in cancer patients.
abstract: We determined morphine plasma concentrations in 6 cancer patients before and with administration of diclofenac for 5 days. The non-steroidal anti-inflammatory drug does not modify morphine bioavailability. This observation suggests that diclofenac can be used in association with morphine during cancer pain treatment, without increasing the risk of overdosage or side effects of the opiate.
authors.affiliation: Pain Therapy and Palliative Care Division, National Cancer Institute, MilanItaly Department of Pharmacology, University of Milan, MilanItaly.
authors.forename: Franco
authors.initials: F
authors.lastname: De Conno
authors.forename: Carla
authors.initials: C
authors.lastname: Ripamonti
authors.forename: Mauro
authors.initials: M
authors.lastname: Bianchi
authors.forename: Vittorio
authors.initials: V
authors.lastname: Ventafridda
authors.forename: Alberto E
authors.initials: AE
authors.lastname: Panerai
mesh_terms: D000368:Aged; D001682:Biological Availability; D002851:Chromatography, High Pressure Liquid; D004008:Diclofenac / Q000009:adverse effects*; D004347:Drug Interactions; D006207:Half-Life; D006801:Humans; D008875:Middle Aged; D009020:Morphine / Q000493:pharmacokinetics* / Q000627:therapeutic use; D009369:Neoplasms / Q000378:metabolism* / Q000503:physiopathology; D010146:Pain / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism*
chemical_list: D004008:Diclofenac; D009020:Morphine